A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Clinical trial NCT07106671 · RECRUITING

Trial details

NCT number: NCT07106671
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

CRS - Cytokine Release Syndrome Myeloma

Start date: 2025-08-10
Primary completion: 2026-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.